These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Inhibition of platelet thromboxane synthetase by sulfasalazine. Stenson WF; Lobos E Biochem Pharmacol; 1983 Jul; 32(14):2205-9. PubMed ID: 6135423 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of thromboxane synthetase by OKY-1581 stimulates the formation of PGE2, PGF2 alpha, PGD2 and 6-keto-PGF1 alpha in human platelets. Uotila P; Matintalo M Prostaglandins Leukot Med; 1984 Apr; 14(1):41-6. PubMed ID: 6427791 [TBL] [Abstract][Full Text] [Related]
4. Thromboxane synthetase inhibitors as pharmacological tools: differential biochemical and biological effects on platelet suspensions. Needleman P; Bryan B; Wyche A; Bronson SD; Eakins K; Ferrendelli JA; Minkes M Prostaglandins; 1977 Nov; 14(5):897-907. PubMed ID: 594391 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of human platelet thromboxane synthetase by 9,11-azoprosta-5,13-dienoic acid. Gorman RR; Bundy GL; Peterson DC; Sun FF; Miller OV; Fitzpatrick FA Proc Natl Acad Sci U S A; 1977 Sep; 74(9):4007-11. PubMed ID: 269449 [TBL] [Abstract][Full Text] [Related]
6. Determination of the formation of thromboxane B2 (TxB2), 12L-hydroxy-5,8,10 heptadecatrienoic acid (HHT) and 12L-hydroxy-5,8,10,14 eicosatrienoic acid (HETE) from arachidonic acid and of the TxB2 :HHT, TxB2 :HETE and (TxB2 +HHT) :HETE ratio in human platelets. Possible use in diagnostic purposes. Vincent JE; Zijlstra FJ; van Vliet H Prostaglandins Med; 1980 Aug; 5(2):79-84. PubMed ID: 7413847 [TBL] [Abstract][Full Text] [Related]
7. Kinetic studies on the conversion of prostaglandin endoperoxide PGH2 by thromboxane synthase. Anderson MW; Crutchley DJ; Tainer BE; Eling TE Prostaglandins; 1978 Oct; 16(4):563-70. PubMed ID: 725086 [TBL] [Abstract][Full Text] [Related]
8. Products, kinetics, and substrate specificity of homogeneous thromboxane synthase from human platelets: development of a novel enzyme assay. Hecker M; Haurand M; Ullrich V; Diczfalusy U; Hammarström S Arch Biochem Biophys; 1987 Apr; 254(1):124-35. PubMed ID: 3579292 [TBL] [Abstract][Full Text] [Related]
9. Familial bleeding tendency with partial platelet thromboxane synthetase deficiency: reorientation of cyclic endoperoxide metabolism. Defreyn G; Machin SJ; Carreras LO; Dauden MV; Chamone DA; Vermylen J Br J Haematol; 1981 Sep; 49(1):29-41. PubMed ID: 6268139 [TBL] [Abstract][Full Text] [Related]
10. Selective effects of two chloromethyl ketones on amino acid and phosphate uptake in rat liver and tumors. Lea MA; Koch MR J Natl Cancer Inst; 1979 Jan; 62(1):181-5. PubMed ID: 281572 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of platelet aggregation by 1-alkylimidazole derivatives, thromboxane A synthetase inhibitors. Kayama N; Sakaguchi K; Kaneko S; Kubota T; Fukuzawa T; Kawamura S; Yoshimoto T; Yamamoto S Prostaglandins; 1981 Apr; 21(4):543-54. PubMed ID: 7196056 [TBL] [Abstract][Full Text] [Related]
12. Differential effect of external calcium on the oxygenated metabolism of endogenous and exogenous arachidonic acid in platelets. Velardo B; Lagarde M Biochem Biophys Res Commun; 1985 Aug; 130(3):1109-14. PubMed ID: 3927915 [TBL] [Abstract][Full Text] [Related]
13. A selective thromboxane synthetase inhibitor blocks the cAMP lowering activity of PGH2. Gorman RR; Fitzpatrick FA; Miller OV Biochem Biophys Res Commun; 1977 Nov; 79(1):305-13. PubMed ID: 200243 [No Abstract] [Full Text] [Related]